Issue link: https://viewer.e-digitaledition.com/i/86099
After imaging tests are completed in an outpatient facility, a frame is placed around the patient's head. Next, a ring is mounted to allow physicians to localize any position within the frame. A fine-slice computed tomography (CT) scan taken after the ring is fixed allows physicians to compare the CT image with the previously conducted MRI imaging, ensuring alignment between the two imaging studies. At that point, physicians frame the plan for radiation delivery. After the path for the radiation is marked, radiation physicists and radia- tion oncologists ensue the treatment plan. Madhur Garg, M.D., Clinical Director, Radiation Oncology, Montefiore Medical Center, and associate professor, radiation oncology and otorhinolaryngology – head and neck surgery, Albert Einstein College of Medicine, explains, "Singe beams of radiation are delivered from multiple angles concentrating on the contoured area for treatment. Carrying only small amounts of radiation, the beams do no harm to the fragile brain tissue until the beams meet at the focal point, where radia- tion concentrates and kills tumor cells. A Novel Weapon in the Arsenal Against Glioblastoma Advances in medical oncology are also critical in the treatment of tumors of the brain and spine. In April, 2011, the U.S. Food and Drug Administration (FDA) approved the NovoTTF – 100A system for use in the treatment of patients with glio- blastoma multiforme after the exhaustion of surgical and radiation treatments. The portable system, operated by battery or power supply, delivers alternating electrical fields, called tumor treatment fields (TTFields), to the patient's head via surface electrodes. According to Jerome Graber, M.D., Director, Adult Neuro- Oncology, Montefiore Medical Center, and assistant professor of neurology and medical oncology, the TTFields have been shown to halt tumor growth and cease the cancer's cell division. He notes that Montefiore Einstein Center for Cancer Care is one of the few New York City area locations certified to treat Further contributing to medical oncol- ogy advances, Montefiore Einstein Center for Cancer Care is currently participating in a Celldex trial to evaluate the efficacy of a vaccine for patients with glioblastoma. glioblastoma patients. Patients who may not tolerate traditional chemotherapy or whose cancers have resisted traditional chemotherapy now have access to this brand new treatment method. For more information about Montefiore Einstein Center for Cancer Care's treatment capabilities for brain and spine tumors, please visit http://www.montefiore.org/ cancer-brain-tumors. ■ MDNEWS.COM ■ MD NEWS Lower Hudson/Bronx | 27

